April 6, 2026
Rx Tariffs: Caveats & MFN Read-Through
The White House’s biopharma tariffs announced last week [Fact Sheet] strike us as an aggressive effort to secure additional onshoring and most favored nation (MFN) pricing agreements with manufacturers, but the clock is likely ticking…